Autologous Costal Osteochondral Transplantation for Talar Osteochondral Lesions

Launched by THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment option for a specific type of ankle injury known as Hepple Stage V talar osteochondral lesions, which are defects in the cartilage of the ankle joint. The researchers want to find out if a procedure called autologous costal osteochondral transplantation, which uses cartilage from the patient's own rib, is more effective and safer than another method that uses bone and tissue from the ankle itself. Participants will be randomly divided into two groups: one will receive the rib cartilage treatment, while the other will get the standard treatment. Both groups will follow the same rehabilitation plan after surgery.

To be eligible for this trial, participants need to be between the ages of 65 and 74 and have a specific type of ankle injury that has not improved with regular treatments for at least six months. They should also have certain symptoms and be willing to take part in the study. However, people with certain other conditions, like joint diseases or significant deformities, won't be able to participate. This study is currently recruiting participants, and those who join will be closely monitored to see how well the treatments work and how they recover.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Symptomatic Hepple stage V talar osteochondral lesions with a lesion depth ≥5 mm and an AOFAS score ≤80 points;
• • Failed conservative treatment for at least 6 months;
• • Unilateral talar osteochondral lesions without corresponding lesions on the tibial side;
• • Willingness to participate in this clinical trial and signing an informed consent form.
• Exclusion Criteria:
• • Combined with lower limb deformity.
• • Combined with hip or knee joint diseases.
• • Combined with ipsilateral ankle arthritis with joint space narrowing .
• • Diagnosis of gouty arthritis of the ankle joint.
• • Combined with osteoporosis (T score \<-2.5).
• • Other conditions considered inappropriate for participation in this clinical trial by the researchers.